Navelbine plus cisplatin in the treatment of advanced non-small cell lung cancer / 中国癌症杂志

ABSTRACT

Purpose:To evaluate the results of combination chemotherapy with navelbine (NVB) and cisplatin (DDP) in patients with stage Ⅲ b—IV non small cell lung cancer (NSCLC), as compared with MVP regimen. Methods:16 cases were treated with MVB+DDP, 20 cases were treated with MVP. Results:The response rate was 50.0% in patients with NVB plus DDP, 40% in those treated with MVP . The major toxic reactions in the two groups were tolerable,being myelo suppression and grstrointestinal reaction. Grade Ⅱ—Ⅳ phlebitis rate was 37.5% in patients with NVB puls DDP, 0.0% in those treated with MVP, respectively ( P 0.05). Conclusions:A higher response rate is attainable with stage Ⅲ b—IV NSCLS treated by navelbine and cisplatin with tolerable toxicity. [